Presentation of contralateral axillary involvement from breast cancer.

Authors

null

Vanessa Prowler

H. Lee Moffitt Cancer Center & Research Institute

Vanessa Prowler , John Kiluk , Marie Lee , Nazanin Khakpour , Christine Laronga , Charles Cox

Organizations

H. Lee Moffitt Cancer Center & Research Institute

Research Funding

No funding sources reported
Background: Metastatic breast cancer to the contralateral axilla is defined as stage IV disease. We postulate that metastatic disease to the contralateral axilla is secondary to extension of aggressive, local regional disease rather than distant metastatic disease and may have a better outcome. Methods: An IRB-approved retrospective review of breast cancer cases presenting to a single institution between January 2005 and December 2011 was performed to identify cases with contralateral axillary disease. Eligibility for the study included unilateral primary breast cancer at presentation with synchronous/metachronous documented metastasis to the contralateral axilla without a documented primary invasive breast cancer within the contralateral breast by surgery or MRI. Clinicopathologic data was recorded for these patients (pts). Results: Thirteen pts were identified that fulfilled eligibility criteria. The average age was 53 years (range 26.3-72.2) with 12/13 (92%) pts presenting with a locally advanced breast tumor or an ipsilateral in-breast recurrence. 10/13 (77%) pts had documented dermal involvement of tumor either at presentation or local recurrence. Contralateral metastatic disease occurred synchronously with the initial primary tumor (3pts, 23%), concomitant with a local recurrence (5 pts, 38%), metachronously with the initial tumor in (3pts, 23%), and metachronously with a local recurrence in (2pts, 15%). Resection of involved contralateral nodes was performed in 10/13 (77%) pts; 5/13 (38%) patients received contralateral axillary radiation; all 13 (100%) received systemic therapy. 9/13 pts (69%) developed distant metastatic disease with a mean follow up of 2.6 years (range 0.3-6.8 years). 3/13 pts (23%) have no evidence of disease at a mean follow up of 4.7 years (range 1.5-6.8). Conclusions: Contralateral axillary spread of breast cancer carries a poor prognosis but may have different prognostic implications than metastatic disease. Contralateral axillary metastatic disease may occur through dermal lymphatic spread and requires multidisciplinary management. Further study is warranted on the prognosis and management of these challenging and rare cases.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2012 Breast Cancer Symposium

Session Type

Poster Session

Session Title

General Poster Session A

Track

Risk Assessment, Prevention, Detection, and Screening

Sub Track

High Risk

Citation

J Clin Oncol 30, 2012 (suppl 27; abstr 49)

DOI

10.1200/jco.2012.30.27_suppl.49

Abstract #

49

Poster Bd #

D10

Abstract Disclosures

Similar Abstracts

First Author: Sameh Hany Emile

First Author: Prantik Das

Abstract

2021 ASCO Annual Meeting

Metastasectomy versus radiation of secondary sites in stage IV breast cancer.

First Author: Nadeem Bilani